![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Eli Lilly Begins Phase 3 Trial of Monoclonal Antibody for COVID-19 Prevention
Eli Lilly Begins Phase 3 Trial of Monoclonal Antibody for COVID-19 Prevention
![Eli Lilly logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Eli-Lilly-logo.gif?t=1616695830&width=430)
August 4, 2020
Eli Lilly has begun a phase 3 trial of its monoclonal antibody LY-CoV555 for prevention of COVID-19 in residents and staff at long-term care facilities.
The study will test if a single dose reduces the rate of SARS-CoV-2 infection through four weeks and COVID-19 complications through eight weeks. It will enroll up to 2,400 residents and staff at facilities that have had a recently diagnosed case of COVID-19 and who are at a high risk of exposure.
The trial will be conducted in collaboration with the NIH’s National Institute of Allergy and Infectious Diseases.
Upcoming Events
-
21Oct